BSD Medical Announces Symposium on Hyperthermia for the Treatment of Cancer at N.N. Blokhin Cancer Center in Russia to Feature BSD's Hyperthermia Systems

BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that the Company's hyperthermia systems will be featured at a symposium focused on image guided hyperthermia treatment of cancer. The symposium will be hosted by the N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences (Blokhin Cancer Center), the leading comprehensive cancer center in Russia, and chaired by Professor Mikhail Davydov M.D. Ph.D., President of the Russian Academy of Medical Sciences and Director of the Blokhin Cancer Center. The symposium, "The Role of Hybrid Hyperthermia in the Therapy of Oncological Diseases," will be held on Nov. 29, 2013, in Moscow, Russia. The Blokhin Cancer Center comprises four separate Institutes, including a 1,600-bed hospital devoted to cancer patients. It is one of the largest hospitals in Europe and is part of the American-Russian Cancer Alliance, which also includes prominent U.S. cancer treatment centers. The U.S. National Cancer Institute (NCI) provides the infrastructure for the Alliance. The symposium was arranged following a request from Blokhin Cancer Center to host the hyperthermia symposium. The conference will feature presentations by leading scientists of the latest research and clinical results on hyperthermia, and BSD's equipment will be featured prominently in these presentations.

"We are proud to be invited to participate in a hyperthermia symposium hosted by the prestigious Blokhin Cancer Center," stated Dr. Gerhard Sennewald, CEO of Medizintechnik Gmbh, BSD’s distributor in Russia. "The symposium will feature presentations on the clinical benefits of hyperthermia for the treatment of cancer using BSD's hyperthermia systems. Following early successful clinical trials on rectal cancer, hyperthermia continues to be a well recognized cancer treatment modality in Russia. All of BSD’s hyperthermia systems are registered with the Russian authorities and enjoy a reputation for excellence."

Russia has a population of 149 million and is a potentially lucrative market for medical device companies. The Russian market for medical equipment and supplies is estimated at $6 billion, which puts the Russia market among the top 20 in the world. Around 73% of the medical equipment market in Russia is supplied by non-Russian manufacturers, with the United States, Germany, Japan and China the leading suppliers.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets, and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia), while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market, and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.

This press release may be deemed to contain forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including, among other things, the demand for the Company’s products, the ability of the Company to produce the products to meet the demand, global economic conditions and uncertainties in the geopolitical environment, and other risk factors set forth in the Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking statements in this release are based on limited information currently available to the Company, which is subject to change, and the Company will not necessarily update the information.